How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,867 results for

Follicle Stimulating Hormone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects (PubMed)

Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects 26085887 2015 06 18 2018 11 13 1911-6470 9 3-4 2015 Mar-Apr Canadian Urological Association journal = Journal de l'Association des urologues du Canada Can Urol Assoc J Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects. E226-7 10.5489/cuaj.2874 Pinthus Jehonathan H JH Associate Professor, Department

Full Text available with Trip Pro

2015 Canadian Urological Association Journal

162. Follicle-stimulating hormone treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis. (PubMed)

Follicle-stimulating hormone treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis. The aim of this study is to comprehensively evaluate whether FSH administration to the male partner of infertile couples improves pregnancy rate, spontaneously and/or after assisted reproductive techniques (ART).Meta-analysis of controlled clinical trials in which FSH was administered for male idiopathic infertility, compared with placebo or no treatment. Randomization

Full Text available with Trip Pro

2015 Endocrine connections

163. Follicle-stimulating hormone receptor polymorphism affects the outcome of ovulation induction in normogonadotropic (World Health Organization class 2) anovulatory subfertility. (PubMed)

Follicle-stimulating hormone receptor polymorphism affects the outcome of ovulation induction in normogonadotropic (World Health Organization class 2) anovulatory subfertility. To assess whether an FSH receptor polymorphism (Asn680Ser, rs6166) can affect the outcome of ovulation induction in normogonadotropic (World Health Organization class 2 [WHO2]) anovulatory subfertile women.Prospective, longitudinal, cohort study.University-based fertility unit.A total of 240 consecutive women diagnosed

2015 Fertility and Sterility

164. Functional characterization of two naturally occurring mutations (Val<sup>514</sup>Ala and Ala<sup>575</sup>Val) in follicle stimulating hormone receptor. (PubMed)

Functional characterization of two naturally occurring mutations (Val514Ala and Ala575Val) in follicle stimulating hormone receptor. Inactivating mutations have been reported in subjects with primary/secondary amenorrhea, whereas activating mutations are rare and seen only in women with ovarian hyperstimulation syndrome (OHSS). In the present study, we describe the functional characterization of the two mutations Val(514)Ala (novel mutation) and Ala(575)Val in FSH receptor (...) type or each of the mutant receptor were generated using Chinese hamster ovary cells. Functional characteristics of both the mutant receptors were assessed by a radioreceptor assay and a cAMP assay.The mutant receptor 514 showed increased cell surface expression as compared with the wild-type (WT) receptor. Although the hormone binding characteristics were similar to the WT receptor, its signaling activity was distinctly higher at lower dose of FSH as monitored by a cAMP assay. On the other hand

Full Text available with Trip Pro

2015 Journal of Clinical Endocrinology and Metabolism

165. Association between Two Polymorphisms of Follicle Stimulating Hormone Receptor Gene and Susceptibility to Polycystic Ovary Syndrome: a Meta-analysis. (PubMed)

Association between Two Polymorphisms of Follicle Stimulating Hormone Receptor Gene and Susceptibility to Polycystic Ovary Syndrome: a Meta-analysis. To investigate the association between two polymorphisms of follicle stimulating hormone receptor (FSHR) gene and polycystic ovary syndrome (PCOS) susceptibility.Case-control studies on relationship of Thr307Ala and Asn680Ser polymorphisms in FSHR gene and PCOS susceptibility were searched from PubMed, ISI web of knowledge, EBSCO, and China

2015 Chinese medical sciences journal = Chung-kuo i hsüeh k'o hsüeh tsa chih / Chinese Academy of Medical Sciences

166. Follicle-stimulating hormone as a predictor for sperm retrieval rate in patients with nonobstructive azoospermia: a systematic review and meta-analysis. (PubMed)

Follicle-stimulating hormone as a predictor for sperm retrieval rate in patients with nonobstructive azoospermia: a systematic review and meta-analysis. Noninvasive parameters for predicating sperm retrieval rate (SRR) are desirables. Follicle-stimulating hormone (FSH) has been an important predictor since the first years of testicular sperm extraction. Recent studies showed continuous interests in FSH, with both pros and cons. Thus, we conducted a meta-analysis to evaluate the diagnostic value

Full Text available with Trip Pro

2015 Asian journal of andrology

167. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer (PubMed)

Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer Treatment of advancing prostate cancer focuses on blocking the activation of the androgen receptor with resultant prolonged perturbation of the hypothalamic-pituitary-gonadal axis. Androgen deprivation therapy (ADT) is marked, however, by eventual progression to castration- resistant prostate cancer (CRPC). Emerging evidence has postulated that follicle-stimulating hormone (FSH) may

Full Text available with Trip Pro

2015 Canadian Urological Association Journal

168. Correlation analysis for follicle-stimulating hormone and C-terminal cross-linked telopetides of type i collagen in menopausal transition women with osteoporosis (PubMed)

Correlation analysis for follicle-stimulating hormone and C-terminal cross-linked telopetides of type i collagen in menopausal transition women with osteoporosis The sudden drop in estrogen in post-menopausal women can lead to osteoporosis. About one in three women aged more than 50 years experienced an osteoporotic fracture. The aim of this study is to explore function of follicle-stimulating hormone (FSH) in bone metabolism and osteoporosis in menopausal transition women. 164 cases of women

Full Text available with Trip Pro

2015 International journal of clinical and experimental medicine

169. Comparison of Follicle-Stimulating Hormone Glycosylation Microheterogenity by Quantitative Negative Mode Nano-Electrospray Mass Spectrometry of Peptide-N Glycanase-Released Oligosaccharides (PubMed)

Comparison of Follicle-Stimulating Hormone Glycosylation Microheterogenity by Quantitative Negative Mode Nano-Electrospray Mass Spectrometry of Peptide-N Glycanase-Released Oligosaccharides Glycans from six highly purified hFSH preparations were released by peptide-N-glycanase digestion and analyzed by negative mode nano-ESI mass spectrometry before and after neuraminidase digestion. Pituitary glycan structures were mainly high-mannose, di-, tri-, and tetra-antennary, and their abundance

Full Text available with Trip Pro

2015 Journal of glycomics & lipidomics

170. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

171. Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women. (PubMed)

Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women. XM17 is a recombinant human follicle-stimulating hormone (follitropin alfa) for stimulation of multifollicular development in women undergoing controlled ovarian hyper-stimulation during assisted reproductive therapy and for treatment of anovulation. Manufactured using Chinese hamster ovary cells transfected with the human (...) follicle-stimulating hormone gene, XM17 has an identical amino acid sequence to that of the human protein as well as to those of the other approved recombinant human follicle-stimulating hormone products. Glycosylation patterns may differ slightly between products. The objectives of this first-in-human study were to assess the safety, tolerability, pharmacokinetics, and dose-proportionality of single ascending subcutaneous doses of XM17 in healthy young female volunteers.Endogenous follicle-stimulating

Full Text available with Trip Pro

2015 International journal of women's health Controlled trial quality: uncertain

172. Dose-Exposure Proportionality of a Novel Recombinant Follicle-Stimulating Hormone (rFSH), FE 999049, Derived from a Human Cell Line, with Comparison Between Caucasian and Japanese Women After Subcutaneous Administration (PubMed)

Dose-Exposure Proportionality of a Novel Recombinant Follicle-Stimulating Hormone (rFSH), FE 999049, Derived from a Human Cell Line, with Comparison Between Caucasian and Japanese Women After Subcutaneous Administration FE 999049 is a novel recombinant follicle-stimulating hormone (rFSH) preparation expressed by a human cell line (PER.C6(®)), in contrast to existing rFSH preparations expressed by Chinese hamster ovary (CHO) cell lines. Since the individual dose of rFSH may be altered depending

Full Text available with Trip Pro

2015 Clinical drug investigation Controlled trial quality: uncertain

173. Treatment of idiopathic oligozoospermia with recombinant human follicle-stimulating hormone: a prospective, randomized double-blind, placebo-controlled clinical study in Chinese population. (PubMed)

Treatment of idiopathic oligozoospermia with recombinant human follicle-stimulating hormone: a prospective, randomized double-blind, placebo-controlled clinical study in Chinese population. Follicle-stimulating hormone plays a crucial role in spermatogenesis. The aim of this study was to evaluate the efficacy of treatment with FSH in Chinese infertility population.Prospective, randomized, double-blind, placebo-controlled clinical study.A total of 354 men affected by idiopathic oligozoospermia

2015 Clinical endocrinology Controlled trial quality: uncertain

174. [Using an ovarian drilling by hydrolaparoscopy or recombinant follicle stimulating hormone plus metformin to treat polycystic ovary syndrome: Why a randomized controlled trial fail?] (PubMed)

[Using an ovarian drilling by hydrolaparoscopy or recombinant follicle stimulating hormone plus metformin to treat polycystic ovary syndrome: Why a randomized controlled trial fail?] To evaluate pregnancy rates after randomized controlled trial (RCT) between ovarian drilling by fertiloscopy or ovarian hyperstimulation+insemination+metformine after clomifène citrate (cc) treatment fails.Randomized controlled trial with 126 patients in each arm in 9 university centers. After 6-9 months (...) of stimulation by cc, 2 groups were randomized: group 1, ovarian drilling with bipolar energy versus group 2: 3 months treatment by metformine followed by 3 hyperstimulation by FSH+insemination. The success rate was pregnancy rate above 12 weeks.RCT was stopped after the screening of 40 patients. In spite of the low number of patients, the pregnancy rate is significantly higher in medical group 8/16 versus 3/18 (p=0.04).The causes of fail of RCT were in relationship with difficulties of inclusion

2015 Journal de gynécologie, obstétrique et biologie de la reproduction Controlled trial quality: uncertain

175. Advantages of Recombinant Follicle-Stimulating Hormone over Human Menopausal Gonadotropin in Intrauterine Insemination: A Randomized Clinical Trial in Polycystic Ovary Syndrome-Associated Infertility. (PubMed)

Advantages of Recombinant Follicle-Stimulating Hormone over Human Menopausal Gonadotropin in Intrauterine Insemination: A Randomized Clinical Trial in Polycystic Ovary Syndrome-Associated Infertility. Various gonadotropin preparations have been used for ovarian stimulation in intrauterine insemination (IUI). The purpose of the current study was to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (rFSH) combined with clomiphene citrate (CC) in IUI cycles (...) . The number of stimulated follicles reaching >17 mm diameter was comparable between groups, but the mean follicular diameter was significantly higher in the rFSH group. The endometrium was also significantly thicker at the time of human chorionic gonadotropin administration in the rFSH group. However, pregnancy outcomes, including the rates of clinical pregnancy, ongoing pregnancy, live birth, miscarriage, ovarian hyperstimulation syndrome and cancellation, were similar between groups.IUI cycles in which

2015 Gynecologic and obstetric investigation Controlled trial quality: uncertain

176. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. (PubMed)

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. To compare antimüllerian hormone (AMH) and antral follicle count (AFC) as predictors of ovarian response to controlled ovarian stimulation at individual fertility clinics.Retrospective analysis of individual study center data in two multicenter trials. Centers that provided (...) agonist and GnRH antagonist trials, respectively.Antimüllerian hormone was a stronger predictor of ovarian response to gonadotropin therapy than AFC at the study center level in both randomized trials utilizing GnRH agonist and GnRH antagonist protocols. Antral follicle count provided no added predictive value beyond AMH.Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Full Text available with Trip Pro

2015 Fertility and Sterility Controlled trial quality: uncertain

177. Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation. (PubMed)

Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation. XM17 is a recombinant human follicle-stimulating hormone (rhFSH) intended mainly for use in controlled ovarian hyperstimulation and the treatment of anovulation. The purpose of the current study was to establish bioequivalence, safety and tolerability of single 300-IU subcutaneous (sc) doses

Full Text available with Trip Pro

2015 Reproductive biology and endocrinology : RB&E Controlled trial quality: uncertain

178. Superovulatory response in Japanese Black cows receiving a single subcutaneous porcine follicle-stimulating hormone treatment or six intramuscular treatments over three days. (PubMed)

Superovulatory response in Japanese Black cows receiving a single subcutaneous porcine follicle-stimulating hormone treatment or six intramuscular treatments over three days. To reduce labor for superovulation treatment by twice-daily intramuscular (im) administration of FSH for more than 3 to 4 days, we investigated the superovulatory responses of Japanese Black cows to porcine FSH (pFSH) used as a single subcutaneous (sc) administration at two different doses in two different volumes

2015 Theriogenology Controlled trial quality: uncertain

179. Does oral Myo-Inositol treatment reduce the amount of recombinant follicle stimulating hormone necessary for ovulation induction and days of ovarian stimulation during assisted reproductive technology? A systematic review for cost-effectiveness analysis

Does oral Myo-Inositol treatment reduce the amount of recombinant follicle stimulating hormone necessary for ovulation induction and days of ovarian stimulation during assisted reproductive technology? A systematic review for cost-effectiveness analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2017 PROSPERO

180. Ovarian stimulation in intra uterine insemination with clomiphene citrate, letrozole or follicle stimulating hormone? An individual patient data meta-analysis

Ovarian stimulation in intra uterine insemination with clomiphene citrate, letrozole or follicle stimulating hormone? An individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2017 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>